← Back
$TEVA All transactions

TEVA PHARMACEUTICAL INDUSTRIES LTD

A

$ Value

$0

Shares

148,016

Price

$0

Filed

May 19

Insider

Name

Lippman Evan

Title

EVP, Business Development

CIK

0002062834

Roles

Officer

Transaction Details

Transaction Date

2025-05-14

Code

A

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

148,016

Footnotes

Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. | Restricted share units were granted on May 14, 2025 with 11,841 vesting on each of May 14, 2026, May 14, 2027 and May 14, 2028, and 11,842 vesting on May 14, 2029. | The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. | Restricted share units were granted on May 14, 2025 with 74,008 vesting on May 14, 2026, and 37,004 vesting on each of May 14, 2027 and May 14, 2028.

Filing Info

Accession No.

0000950170-25-074286

Form Type

4

Issuer CIK

0000818686

Lippman Evan's History

Date Ticker Type Value
2026-03-04 TEVA A $0
2025-05-14 TEVA A $0
2025-05-14 TEVA A $0

Other Insiders at TEVA (90d)

Insider Bought Sold Last
Francis Richard D
President and CEO
$31.1M 2026-03-05
Sabag Mark
See "Remarks"
2026-03-05
Daniell Richard
EVP, Europe Commercial
$7.7M 2026-03-05
Daniell Richard
Exec. VP, European Commercial
2026-01-27
Kalif Eliyahu Sharon
EVP, Chief Financial Officer
$11.6M 2026-03-05
Weiss Amir
Chief Accounting Officer
2026-03-05
Hughes Eric A
See "Remarks"
$3.3M 2026-03-05
Fox Christine
EVP, U.S. Commercial
$546K 2026-03-05
Shields Matthew
EVP, Global Operations
$548K 2026-03-05
Jover Placid
See "Remarks"
$448K 2026-03-05
Lippman Evan
EVP, Business Development
2026-03-04
Savage Brian
Interim Chief Legal Officer
$164K 2026-03-05